A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee
Latest Information Update: 07 Apr 2025
At a glance
- Drugs CYT 108 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Cytonics Corporation
Most Recent Events
- 01 Apr 2025 According to Cytonics Corporation media release, Phase 1 is now complete, and the team is focused on cleaning and locking the database.
- 01 Apr 2025 Status changed from active, no longer recruiting to completed. The last patient has completed their last visit.
- 21 Jan 2025 According to Cytonics Corporation media release,first nine patients in this trial successfully completed the study.